Broad sarbecovirus neutralization by a human monoclonal antibody.
Animals
Antibodies, Monoclonal
/ chemistry
Antibodies, Viral
/ chemistry
Broadly Neutralizing Antibodies
/ chemistry
COVID-19
/ immunology
Cross Reactions
/ immunology
Disease Models, Animal
Female
Humans
Immune Evasion
/ genetics
Mesocricetus
/ immunology
Mutation
Neutralization Tests
SARS-CoV-2
/ chemistry
Viral Zoonoses
/ immunology
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
29
03
2021
accepted:
09
07
2021
pubmed:
20
7
2021
medline:
9
9
2021
entrez:
19
7
2021
Statut:
ppublish
Résumé
The recent emergence of SARS-CoV-2 variants of concern
Identifiants
pubmed: 34280951
doi: 10.1038/s41586-021-03817-4
pii: 10.1038/s41586-021-03817-4
pmc: PMC9341430
mid: NIHMS1824866
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Viral
0
Broadly Neutralizing Antibodies
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-108Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM120553
Pays : United States
Organisme : NIAID NIH HHS
ID : DP1 AI158186
Pays : United States
Organisme : NIH HHS
ID : S10 OD023476
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM133894
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201700059C
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008268
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI141707
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM136534
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Deng, X. et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184, 3426–3437 (2021).
pubmed: 33991487
pmcid: 8057738
doi: 10.1016/j.cell.2021.04.025
Challen, R. et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. Br. Med. J. 372, n579 (2021).
doi: 10.1136/bmj.n579
Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabg3055 (2021).
pubmed: 33658326
pmcid: 8128288
doi: 10.1126/science.abg3055
Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021).
pubmed: 33690265
doi: 10.1038/s41586-021-03402-9
McCallum, M. et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science https://doi.org/10.1126/science.abi7994 (2021).
Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622 (2021).
pubmed: 33567448
doi: 10.1038/s41586-021-03324-6
pmcid: 8503938
Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 593, 136–141 (2021).
pubmed: 33706364
doi: 10.1038/s41586-021-03412-7
Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27, 622–625 (2021).
pubmed: 33654292
doi: 10.1038/s41591-021-01285-x
Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021).
pubmed: 33664494
doi: 10.1038/s41591-021-01294-w
pmcid: 8058618
Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1885–1898 (2021).
pubmed: 33725432
doi: 10.1056/NEJMoa2102214
Tortorici, M. A. & Veesler, D. Structural insights into coronavirus entry. Adv. Virus Res. 105, 93–116 (2019).
pubmed: 31522710
pmcid: 7112261
doi: 10.1016/bs.aivir.2019.08.002
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292 (2020).
pubmed: 32155444
pmcid: 7102599
doi: 10.1016/j.cell.2020.02.058
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
pubmed: 32075877
pmcid: 7164637
doi: 10.1126/science.abb2507
Kuhn, J. H., Li, W., Choe, H. & Farzan, M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell. Mol. Life Sci. 61, 2738–2743 (2004).
pubmed: 15549175
pmcid: 7079798
doi: 10.1007/s00018-004-4242-5
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020).
pubmed: 32142651
pmcid: 7102627
doi: 10.1016/j.cell.2020.02.052
Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562–569 (2020).
pubmed: 32094589
doi: 10.1038/s41564-020-0688-y
Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024–1042 (2020).
pubmed: 32991844
pmcid: 7494283
doi: 10.1016/j.cell.2020.09.037
Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 371, 735–741 (2021).
pubmed: 33436524
pmcid: 7928838
doi: 10.1126/science.abf6840
Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633 (2020).
pubmed: 32245784
pmcid: 7164391
doi: 10.1126/science.abb7269
Rappazzo, C. G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science 371, 823–829 (2021).
pubmed: 33495307
pmcid: 7963221
doi: 10.1126/science.abf4830
Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 370, 950–957 (2020).
pubmed: 32972994
pmcid: 7857395
doi: 10.1126/science.abe3354
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
pubmed: 32422645
doi: 10.1038/s41586-020-2349-y
Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593, 270–274 (2021).
pubmed: 33723411
doi: 10.1038/s41586-021-03426-1
Thomson, E. C. et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184, 1171–1187 (2021).
pubmed: 33621484
pmcid: 7843029
doi: 10.1016/j.cell.2021.01.037
Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021).
pubmed: 33853970
pmcid: 8139423
doi: 10.1126/science.abh2644
Starr, T. N. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature https://doi.org/10.1038/s41586-021-03807-6 (2021).
Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682–687 (2020).
pubmed: 33045718
pmcid: 8092461
doi: 10.1038/s41586-020-2852-1
Cathcart, A L. et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. Preprint at https://doi.org/10.1101/2021.03.09.434607 (2021).
Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295–1310 (2020).
pubmed: 32841599
pmcid: 7418704
doi: 10.1016/j.cell.2020.08.012
Case, J. B. et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe 28, 465–474 (2020).
pubmed: 32798445
pmcid: 7391951
doi: 10.1016/j.chom.2020.07.018
Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477–488 (2021).
pubmed: 33535027
pmcid: 7839837
doi: 10.1016/j.chom.2021.01.014
Huo, J. et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. Cell Host Microbe 28, 445–454.e6 (2020).
pubmed: 32585135
pmcid: 7303615
doi: 10.1016/j.chom.2020.06.010
Walls, A. C. et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell 176, 1026–1039 (2019).
pubmed: 30712865
pmcid: 6751136
doi: 10.1016/j.cell.2018.12.028
Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731–736 (2020).
pubmed: 32540900
pmcid: 7299279
doi: 10.1126/science.abc7424
Wrobel, A. G. et al. Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. Nat. Commun. 11, 5337 (2020).
pubmed: 33087721
pmcid: 7577971
doi: 10.1038/s41467-020-19146-5
Boudewijns, R. et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 11, 5838 (2020).
pubmed: 33203860
pmcid: 7672082
doi: 10.1038/s41467-020-19684-y
Schäfer, A. et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J. Exp. Med. 218, e20201993 (2021).
pubmed: 33211088
doi: 10.1084/jem.20201993
Winkler, E. S. et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection. Cell 184,1804–1820 (2021).
pubmed: 33691139
pmcid: 7879018
doi: 10.1016/j.cell.2021.02.026
Abdelnabi, R. et al. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. EBioMedicine 68, 103403 (2021).
pubmed: 34049240
pmcid: 8143995
doi: 10.1016/j.ebiom.2021.103403
Walls, A. C. et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Preprint at https://doi.org/10.1101/2021.03.15.435528 (2021).
Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508–1513 (2015).
pubmed: 26552008
pmcid: 4797993
doi: 10.1038/nm.3985
Menachery, V. D. et al. SARS-like WIV1-CoV poised for human emergence. Proc. Natl Acad. Sci. USA 113, 3048–3053 (2016).
pubmed: 26976607
pmcid: 4801244
doi: 10.1073/pnas.1517719113
Ge, X. Y. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535–538 (2013).
pubmed: 24172901
pmcid: 5389864
doi: 10.1038/nature12711
Martinez, D. R. et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science https://doi.org/10.1126/science.abi4506 (2021).
Makarenkov, V., Mazoure, B., Rabusseau, G. & Legendre, P. Horizontal gene transfer and recombination analysis of SARS-CoV-2 genes helps discover its close relatives and shed light on its origin. BMC Ecol. Evol. 21, 5 (2021).
pubmed: 33514319
pmcid: 7817968
doi: 10.1186/s12862-020-01732-2
Greaney, A. J. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463–476 (2021).
pubmed: 33592168
pmcid: 7869748
doi: 10.1016/j.chom.2021.02.003
Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367–1382 (2020).
pubmed: 33160446
pmcid: 7604136
doi: 10.1016/j.cell.2020.10.043
Pinto, D. et al. Structural basis for broad HIV-1 neutralization by the MPER-specific human broadly neutralizing antibody LN01. Cell Host Microbe 26, 623–637 (2019).
pubmed: 31653484
pmcid: 6854463
doi: 10.1016/j.chom.2019.09.016
Slater, G. S. C & Birney, E. Automated generation of heuristics for biological sequence comparison. BMC Bioinformatics 6, 31 (2005).
pubmed: 15713233
pmcid: 553969
doi: 10.1186/1471-2105-6-31
Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772–780 (2013).
pubmed: 23329690
pmcid: 3603318
doi: 10.1093/molbev/mst010
Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).
pubmed: 32221306
pmcid: 7100515
doi: 10.1038/s41467-020-15562-9
Crawford, K. H. D. et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12, 513 (2020).
pmcid: 7291041
doi: 10.3390/v12050513
Takada, A. et al. A system for functional analysis of Ebola virus glycoprotein. Proc. Natl Acad. Sci. USA 94, 14764–14769 (1997).
pubmed: 9405687
pmcid: 25111
doi: 10.1073/pnas.94.26.14764
Xie, X. et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat. Commun. 11, 5214 (2020).
pubmed: 33060595
pmcid: 7567097
doi: 10.1038/s41467-020-19055-7
Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493–497 (1938).
doi: 10.1093/oxfordjournals.aje.a118408
Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44–57 (2021).
pubmed: 33259788
pmcid: 7676316
doi: 10.1016/j.chom.2020.11.007
Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850–854 (2021).
pubmed: 33495308
pmcid: 7963219
doi: 10.1126/science.abf9302
Kabsch, W. Xds. Acta Crystallogr. D 66, 125–132 (2010).
pubmed: 20124692
pmcid: 2815665
doi: 10.1107/S0907444909047337
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
pubmed: 19461840
pmcid: 2483472
doi: 10.1107/S0021889807021206
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
pubmed: 20383002
pmcid: 2852313
doi: 10.1107/S0907444910007493
Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D 74, 519–530 (2018).
doi: 10.1107/S2059798318002425
Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D 67, 355–367 (2011).
pubmed: 21460454
pmcid: 3069751
doi: 10.1107/S0907444911001314
Suloway, C. et al. Automated molecular microscopy: the new Leginon system. J. Struct. Biol. 151, 41–60 (2005).
pubmed: 15890530
doi: 10.1016/j.jsb.2005.03.010
Tegunov, D. & Cramer, P. Real-time cryo-electron microscopy data preprocessing with Warp. Nat. Methods 16, 1146–1152 (2019).
pubmed: 31591575
pmcid: 6858868
doi: 10.1038/s41592-019-0580-y
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
pubmed: 28165473
doi: 10.1038/nmeth.4169
Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).
pubmed: 30412051
pmcid: 6250425
doi: 10.7554/eLife.42166
Kimanius, D., Forsberg, B. O., Scheres, S. H. & Lindahl, E. Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. eLife 5, e18722 (2016).
pubmed: 27845625
pmcid: 5310839
doi: 10.7554/eLife.18722
Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214–1221 (2020).
pubmed: 33257830
doi: 10.1038/s41592-020-00990-8
Zivanov, J., Nakane, T. & Scheres, S. H. W. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ 6, 5–17 (2019).
pubmed: 30713699
pmcid: 6327179
doi: 10.1107/S205225251801463X
Chen, S. et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24–35 (2013).
pubmed: 23872039
pmcid: 3834153
doi: 10.1016/j.ultramic.2013.06.004
Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
pubmed: 15264254
doi: 10.1002/jcc.20084
Frenz, B. et al. Automatically fixing errors in glycoprotein structures with Rosetta. Structure 27, 134–139 (2019).
pubmed: 30344107
doi: 10.1016/j.str.2018.09.006
Wang, R. Y. et al. Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta. eLife 5, e17219 (2016).
pubmed: 27669148
pmcid: 5115868
doi: 10.7554/eLife.17219
Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D 75, 861–877 (2019).
doi: 10.1107/S2059798319011471
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010).
pubmed: 20057044
doi: 10.1107/S0907444909042073
Agirre, J. et al. Privateer: software for the conformational validation of carbohydrate structures. Nat. Struct. Mol. Biol. 22, 833–834 (2015).
pubmed: 26581513
doi: 10.1038/nsmb.3115
Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).
pubmed: 28710774
doi: 10.1002/pro.3235
Pinto, D. et al. A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery. Preprint at https://doi.org/10.1101/2021.05.09.442808 (2021).